本帖最后由 老马 于 2012-1-13 21:20 编辑
2 L+ b b0 W8 |* \# r6 {1 C0 N- M5 I' t; `8 s" P! v
爱必妥和阿瓦斯丁的比较: l p2 U' c6 t' F% i" }2 ^: H
- t# U$ k3 D$ N; W* f7 @$ C
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 O7 D/ j4 `) p, L# B) O
( X( B. C3 P/ e( ~/ A
5 q- E( ]+ K" N5 f5 z
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/2 e: P9 i2 ~$ o: n
==================================================
/ Y2 ]" Y3 {& n* y2 vOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); ]' c2 E7 `0 p& U' ]# o: L9 D/ O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ?- d0 F; i8 K. N! x q' c- y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.% o: L4 o! R5 z R4 z
|
显身卡
